Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-022-05766-0
Abstract: Fibroblast activation protein (FAP) and its inhibitors (FAPI) have attracted tremendous attention worldwide over the last several years [1–4]. A number of radiolabeled FAPI have been designed, synthesized, and evaluated in preclinical models, and many… read more here.
Keywords: cancer; tumor; medicine; albumin binding ... See more keywords
Albumin binding function is a novel biomarker for early liver damage and disease progression in non-alcoholic fatty liver disease
Sign Up to like & getrecommendations! Published in 2020 at "Endocrine"
DOI: 10.1007/s12020-020-02319-z
Abstract: Purpose Indicators to assess early liver damage and disease progression in nonalcoholic fatty liver disease (NAFLD) remain unsatisfactory. Albumin binding function has been reported to be an early indicator of liver damage in hepatitis and… read more here.
Keywords: albumin binding; liver damage; disease; binding function ... See more keywords
Novel auristatin E‐based albumin‐binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Controlled Release"
DOI: 10.1016/j.jconrel.2019.01.010
Abstract: ABSTRACT Auristatins are a class of highly cytotoxic tubulin‐disrupting peptides, which have shown limited therapeutic effect as free agents in clinical trials. In our continuing effort to develop acid‐sensitive albumin‐binding anticancer drugs exploiting circulating serum… read more here.
Keywords: sulf07; binding prodrugs; albumin binding; auristatin ... See more keywords
86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00579
Abstract: Fibroblast activation protein inhibitor (FAPI) is a novel quinoline-based radiopharmaceutical that has theranostic potential, yet the limited tumor retention hinders late-time diagnosis and radionuclide treatment. This study synthesized four albumin-binding FAPIs (TE-FAPI-01 to 04) and… read more here.
Keywords: activation protein; fapi; albumin binding; fibroblast activation ... See more keywords
Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1
Sign Up to like & getrecommendations! Published in 2020 at "RSC Advances"
DOI: 10.1039/d0ra00104j
Abstract: Currently, the curative effects of polypeptide drugs are often restricted due to the short in vivo duration of action. In this study, we fused a series of heptapeptide tags with different length fatty chains to… read more here.
Keywords: evaluation novel; albumin binding; glp; thrombin based ... See more keywords
Novel albumin-binding photothermal agent ICG-IBA-RGD for targeted fluorescent imaging and photothermal therapy of cancer
Sign Up to like & getrecommendations! Published in 2021 at "RSC Advances"
DOI: 10.1039/d0ra09653a
Abstract: In this work, we present a novel photothermal agent ICG-IBA-RGD based on albumin-binding strategy for enhanced tumor targeting imaging and photothermal therapy. read more here.
Keywords: photothermal agent; agent icg; iba rgd; icg iba ... See more keywords
An albumin-binding Gd-HPDO3A contrast agent for improved intravascular retention
Sign Up to like & getrecommendations! Published in 2021 at "Inorganic Chemistry Frontiers"
DOI: 10.1039/d1qi00128k
Abstract: A new Gd-HPDO3A derivative with improved MR contrast enhancing efficiency, demonstrated in a murine tumor model and in mouse models for stable and vulnerable atherosclerotic plaques, due to increased intravascular retention. read more here.
Keywords: intravascular retention; albumin binding; contrast; binding hpdo3a ... See more keywords
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2021 at "mAbs"
DOI: 10.1080/19420862.2021.1893888
Abstract: ABSTRACT Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin.… read more here.
Keywords: half life; life; albumin binding; human fcrn ... See more keywords
Abstract B004: Enhanced efficacy of immune modulators with albumin binding domains
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-b004
Abstract: Numerous approaches to improve the biologic half-life and tumor targeting of small therapeutic proteins (e.g., interleukins), peptides, and fragment-based antibodies (scFv) have been described. The attractiveness of these smaller biologic formats includes improved tumor penetration… read more here.
Keywords: therapeutic proteins; albumin binding; efficacy; half life ... See more keywords
Serum albumin binding knob domains engineered within a VH framework III bispecific antibody format and as chimeric peptides
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1170357
Abstract: Background Serum albumin binding is an established mechanism to extend the serum half-life of antibody fragments and peptides. The cysteine rich knob domains, isolated from bovine antibody ultralong CDRH3, are the smallest single chain antibody… read more here.
Keywords: serum albumin; albumin binding; knob domains; framework iii ... See more keywords
New 55Co-labeled Albumin-Binding Folate Derivatives as Potential PET Agents for Folate Receptor Imaging
Sign Up to like & getrecommendations! Published in 2019 at "Pharmaceuticals"
DOI: 10.3390/ph12040166
Abstract: Overexpression of folate receptors (FRs) on different tumor types (e.g., ovarian, lung) make FRs attractive in vivo targets for directed diagnostic/therapeutic agents. Currently, no diagnostic agent suitable for positron emission tomography (PET) has been adopted… read more here.
Keywords: 55co labeled; albumin binding; binding folate; labeled albumin ... See more keywords